(Date:11/21/2008)... Texas Monthly Magazine announced its no...quot; award given to elite dentists in Texas. Dr. ...n nominated a top practitioner in the area of Cosm... TX (PRWEB) November 21, 2008-- Dr. Michael McCart...quot;Texas Monthly Super Dentist" for the thi...
(Date:11/20/2008)...at timing is everything, and that certainly appear...born four months before the height of cold and flu...d asthma than children born at any other time of y...lyzed the birth and medical records of more than 9...etermine whether date of birth in relationship to ...
(Date:11/20/2008)..., DC (November 20, 2008) While the U.S. AIDS epide... failure to widely implement routine HIV testing c...xperts said today. Almost 60,000 Americans were in...70 percent of new sexually transmitted infections ...cted. ,Guidelines issued two years ago by the U....
(Date:11/20/2008)...0 ReachMD, the first satellite rad...edical professionals, announced,today their newes...can Medical,Directors Association (AMDA), the pro...ding physicians, and others practicing in the long...celius, President of AMDA says, "ReachMD provides ...
Breaking Medicine News(10 mins):Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Fall babies: Born to wheeze? 2Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 2Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 3Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 4Health News:Despite national guidelines, private insurers, ER, federal and state agencies fail to routinely test for HIV 5Health News:ReachMD Announces New Strategic Partnership with American Medical Directors Association 2(Date:11/20/2008)...- Milk. It does a body good. And,now it,s doing i... of,research, scientists at OncoNutrition(TM) hav...imulate the body,s own production of antioxidants.... go to:, http://www.prnewswire.com/mnr/eqwestgroup...therapies, the chief scientist, Dr. David,Tsai, d...
(Date:11/20/2008)...l data from a prospective,registry presented this...,treatment with the Trellis(R) Peripheral Infusio..., CA) successfully breaks up the blood clot in mos...hnique, called isolated pharmacomechanical thrombo...y than current catheter-directed thrombolysis,(CD...
(Date:11/19/2008)...e-FirstCall/ -- Amgen,(Nasdaq: AMGN ) and Mille...f,Takeda Pharmaceutical Company Limited (TSE: 405...3 MONET1 trial evaluating motesanib (AMG 706) in,...e first-line treatment of,advanced non-small cell...d,following a planned safety data review of 600 p...
(Date:11/19/2008)...gen, a contract development and,manufacturing org... first,phase launch of its contract facility in D...ss the process, facility and capacity problems com...d, low-volume clinical and,early-stage commercial...s can invest over $100 million and four years to d...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2Protein in human hair shows promise for regenerating nerves 9372 1Protein in human hair shows promise for regenerating nerves 9372 2Protein in human hair shows promise for regenerating nerves 9372 3UT Southwestern scientist honored among best in Texas research 1837 1UT Southwestern scientist honored among best in Texas research 1837 2UT Southwestern scientist honored among best in Texas research 1837 3Smoke Free Workplace Laws Cigarette Taxes on the Rise 9368 1Smoke Free Workplace Laws Cigarette Taxes on the Rise 9368 2Smoke Free Workplace Laws Cigarette Taxes on the Rise 9368 3Smoke Free Workplace Laws Cigarette Taxes on the Rise 9368 4Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 9363 1Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 9363 2Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector 9363 3...BUSINESS WIRE)--Jun 5, 2007 - First-in-human resul... ImClone Systems,Incorporated (NASDAQ: IMCL) and t... 1 receptor), were presented at the annual,meeting...hicago.,The IGF-IR is expressed on the cell surfac... lead to tumor cell growth and,proliferation, and ...
...resented at Society of Nuclear Medicine Annual Mee...tCall/ --,Immunomedics, Inc. , a biopharmaceutical...es to treat cancer and other serious,diseases, tod...tudy,with the Company,s humanized anti-MUC1 monocl...pe, Yttrium-90 (Y-90), in patients with,unresectab...
Other Medicine Technology:Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 2Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal,Antibody IMC-A12 Presented at ASCO 3Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 2Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 3Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 4Immunomedics Reports Initial Clinical Results With Hpam4 For,Pancreatic Cancer Therapy 5Smooth colibri tip; In Titanium.
Fine .12mm Tip With 5mm Platform; In Titanium.
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium.
0.3mm tips; 9.5mm from tips to cross action; in Titanium.
Medicine Products: